Literature DB >> 28654569

Maintaining Interrater Agreement of Core Assessment Instruments in a Multisite Randomized Controlled Clinical Trial: The Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) Trial.

Ruth Lebet1, Jennifer Hayakawa, Tracy B Chamblee, Joana A Tala, Nakul Singh, David Wypij, Martha A Q Curley.   

Abstract

BACKGROUND: RESTORE (Randomized Evaluation of Sedation Titration for Respiratory Failure) was a cluster randomized clinical trial evaluating a sedation strategy in children 2 weeks to <18 years of age with acute respiratory failure supported on mechanical ventilation. A total of 31 U.S. pediatric intensive care units (PICUs) participated in the trial. Staff nurse rater agreement on measures used to assess a critical component of treatment fidelity was essential throughout the 4-year data collection period.
OBJECTIVE: The purpose of the study is to describe the method of establishing and maintaining interrater agreement (IRA) of two core clinical assessment instruments over the course of the clinical trial.
METHODS: IRA cycles were carried out at all control and intervention sites and included a minimum of five measurements of the State Behavioral Scale (SBS) and Withdrawal Assessment Tool-Version 1 (WAT-1). Glasgow Coma Scale scores were also obtained. PICUs demonstrating <80% agreement repeated their IRA cycle. Fleiss's kappa coefficient was used to assess IRA.
RESULTS: Repeated IRA cycles were required for 8% of 226 SBS cycles and 2% of 222 WAT-1 cycles. Fleiss's kappa coefficients from more than 1,350 paired assessments were .86 for SBS and .92 for WAT-1, demonstrating strong agreement and similar to .91 for the Glasgow Coma Scale. There was no difference in Fleiss's kappa for any of the instruments based on unit size or timing of assessment (earlier or later in the study). For SBS scores, Fleiss's kappa was significantly different in larger and smaller PICUs (.82 vs. .92, p = .003); however, Fleiss's kappa for both groups indicated excellent agreement.
CONCLUSION: Monitoring measurement reliability is an essential step in ensuring treatment fidelity and, thus, the validity of study results. Standardization on the use of these core assessment instruments among participating sites was achieved and maintained throughout the trial.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28654569      PMCID: PMC5488692          DOI: 10.1097/NNR.0000000000000224

Source DB:  PubMed          Journal:  Nurs Res        ISSN: 0029-6562            Impact factor:   2.381


  12 in total

Review 1.  The revised CONSORT statement for reporting randomized trials: explanation and elaboration.

Authors:  D G Altman; K F Schulz; D Moher; M Egger; F Davidoff; D Elbourne; P C Gøtzsche; T Lang
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

2.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

3.  Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the NIH Behavior Change Consortium.

Authors:  Albert J Bellg; Belinda Borrelli; Barbara Resnick; Jacki Hecht; Daryl Sharp Minicucci; Marcia Ory; Gbenga Ogedegbe; Denise Orwig; Denise Ernst; Susan Czajkowski
Journal:  Health Psychol       Date:  2004-09       Impact factor: 4.267

4.  The Assessment, Monitoring, and Enhancement of Treatment Fidelity In Public Health Clinical Trials.

Authors:  Belinda Borrelli
Journal:  J Public Health Dent       Date:  2011       Impact factor: 1.821

5.  Beyond statistical significance: clinical interpretation of rehabilitation research literature.

Authors:  Phil Page
Journal:  Int J Sports Phys Ther       Date:  2014-10

6.  Prospective evaluation of sedation-related adverse events in pediatric patients ventilated for acute respiratory failure.

Authors:  Mary Jo C Grant; Lisa A Scoppettuolo; David Wypij; Martha A Q Curley
Journal:  Crit Care Med       Date:  2012-04       Impact factor: 7.598

7.  Validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients.

Authors:  Linda S Franck; Lisa A Scoppettuolo; David Wypij; Martha A Q Curley
Journal:  Pain       Date:  2011-11-16       Impact factor: 6.961

8.  Protocolized sedation vs usual care in pediatric patients mechanically ventilated for acute respiratory failure: a randomized clinical trial.

Authors:  Martha A Q Curley; David Wypij; R Scott Watson; Mary Jo C Grant; Lisa A Asaro; Ira M Cheifetz; Brenda L Dodson; Linda S Franck; Rainer G Gedeit; Derek C Angus; Michael A Matthay
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

Review 9.  Optimal sedation in pediatric intensive care patients: a systematic review.

Authors:  Nienke J Vet; Erwin Ista; Saskia N de Wildt; Monique van Dijk; Dick Tibboel; Matthijs de Hoog
Journal:  Intensive Care Med       Date:  2013-06-19       Impact factor: 17.440

10.  The Withdrawal Assessment Tool-1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients.

Authors:  Linda S Franck; Sion Kim Harris; Deborah J Soetenga; June K Amling; Martha A Q Curley
Journal:  Pediatr Crit Care Med       Date:  2008-11       Impact factor: 3.624

View more
  2 in total

Review 1.  Sedation level with midazolam: A pediatric surgery approach.

Authors:  Carmen Flores-Pérez; Luis Alfonso Moreno-Rocha; Juan Luis Chávez-Pacheco; Norma Angélica Noguez-Méndez; Janett Flores-Pérez; María Fernanda Alcántara-Morales; Luz Cortés-Vásquez; Lina Sarmiento-Argüello
Journal:  Saudi Pharm J       Date:  2022-05-23       Impact factor: 4.562

2.  Association of Race and Ethnicity with Sedation Management in Pediatric Intensive Care.

Authors:  JoAnne E Natale; Lisa A Asaro; Jill G Joseph; Christine Ulysse; Judith Ascenzi; Cindy Bowens; David Wypij; Martha A Q Curley
Journal:  Ann Am Thorac Soc       Date:  2021-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.